For healthcare professionals only
GP Notebook

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Video resources

Dr Sarah Jarvis, General Practitioner and Medical Broadcaster, London

Chair of the T2 Discussions webinar series alongside several experts

How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters

Dr Sarah Jarvis & Professor Richard Holt

How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters

  • Understand the definition, characteristic symptoms and impact of diabetes distress in adults with type 2 diabetes
  • Examine best practice for detecting and measuring diabetes distress
  • Discuss strategies to help support your patients with diabetes distress

Diabetes Distress in adults with type 2 diabetes: Summary

  • What is diabetes distress and why does it matter?
  • The Diabetes UK 7 As model for managing distress

How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?

Dr Sarah Jarvis & Dr Kevin Fernando

How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?

  • Best practice for achieving treatment targets in adults with type 2 diabetes, including how frequently treatment targets should be assessed and key findings from the National Diabetes Audit
  • Practical tips for addressing clinical inertia with our patients
  • The importance of individualising treatment targets and the implications this may have for choice of pharmacotherapy

The impact of clinical inertia on the achievement of treatment targets in adults with type 2 diabetes: Summary

  • The burden of clinical inertia in type 2 diabetes and its role in driving adverse actions
  • The importance of tailoring treatment to the individual and best practices to follow

How and when to switch or add in medications in adult type 2 diabetes

Dr Sarah Jarvis & Philip Newland-Jones

Switching and adding in medications in adult type 2 diabetes

  • Examining the evidence for adding in or switching medications in type 2 diabetes
  • A case-based overview of the when, why and how of adding in or switching medications
  • Considerations following a type 2 diabetes medication review

A pharmacist’s guide to switching and adding in medications in adult type 2 diabetes

  • Key information filter for diabetes therapy choice
  • NICE treatment algorithm for adult type 2 diabetes
  • A practical approach on whether to switch or to add medication

Hypoglycaemia in adult type 2 diabetes

Dr Sarah Jarvis & Su Down

Managing hypoglycaemia in type 2 diabetes

  • Hypoglycaemia: Definition, burden and impact
  • Tips for engaging in conversation to improve patient outcomes – The patient and clinician barriers and how to handle them
  • Resources for discussing hypoglycaemia with type 2 diabetes patients

Hypoglycaemia: Insights from a primary care and patient perspective

  • Insights from a primary care and patient perspective on managing hypoglycaemia in type 2 diabetes
  • The burden of hypoglycaemia
  • Tips for discussing hypoglycaemia with your patients

Managing type 2 diabetes in primary care

Dr Sarah Jarvis, Dr Amrit Lamba & Dr Andrew Frankel

Managing type 2 diabetes in primary care

  • The updated NICE NG28 type 2 diabetes guidance
  • The implications of these changes for day-to-day clinical practice

Convenience of Trajenta (linagliptin) 5 mg once daily in a broad range of people with type 2 diabetes

  • Prescribing linagliptin in people with type 2 diabetes

Management of type 2 diabetes in the elderly and frail

  • The ideal glycaemic targets for the elderly and frail population with type 2 diabetes
  • How to simplify the management of type 2 diabetes in the elderly and frail population
  • The practicalities of treatment with DPP-4 inhibitors, in particular linagliptin

Actively support your adult patients with type 2 diabetes during Ramadan

Dr Sarah Jarvis, Professor Wasim Hanif & Alia Gilani

Supporting your patients during Ramadan

  • How to assess the potential risks associated with fasting
  • Conducting pre-Ramadan medication reviews
  • Offering practical advice to adults with type 2 diabetes who wish to fast

The risks of fasting during Ramadan in adults with type 2 diabetes

  • Potential risks for adults with type 2 diabetes wishing to fast during Ramadan
  • Available screening options for this population

Ramadan fasting: A guide for adults with type 2 diabetes

  • The importance of a pre-Ramadan medication review
  • When a person with diabetes should break their Ramadan fast
  • Diet and exercise advice

Webinar

Sarah Jarvis

Kevin Fernando

The event starts in:

DAYS
HRS
MIN
SEC

Coming soon

Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-107170 V7 | February 2024

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland 
Prescribing information for the Republic of Ireland
Prescribing information for Great Britain and Northern Ireland

This video is for healthcare professionals in the UK and NI only.

This video is intended for healthcare professionals from Great Britain and Northern Ireland only. Please click the button below to confirm that you are based in Great Britain or Northern Ireland

This content is for healthcare professionals in Great Britain and Northern Ireland only.

The content on this page are intended for healthcare professionals from Great Britain and Northern Ireland only. Please click the button below to confirm that you are based in Great Britain or Northern Ireland.

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.
Prescribing information for Great Britain and Northern Ireland
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].


You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.